GlassScriptPhysician profile
Dorothy Blanks
NPI 1356992325
$6,317.18
in general payments reported to CMS, 2019-2025
34 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,316 · 2022: $1,622 · 2023: $1,073 · 2024: $1,074 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $935.42 | 2021-2024 | |
| Abbvie INC. | $890.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $840.22 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $439.46 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $379.55 | 2022 | |
| Gilead Sciences, INC. | $361.48 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $315.68 | 2022-2025 | Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $291.74 | 2021 | |
| Merck Sharp & Dohme LLC | $215.82 | 2023-2024 | Pifeltro, Delstrigo, Dificid |
| Pfizer INC. | $165.42 | 2022-2024 | |
| Amgen INC. | $145.12 | 2024 | Repatha, Otezla |
| Braeburn INC. | $125.00 | 2024 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.02 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.69 | 2024 | Dupixent |
| Viiv Healthcare Company | $120.43 | 2023-2024 | Cabenuva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.18 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $107.60 | 2023 | Quviviq |
| Lilly USA, LLC | $83.39 | 2021-2022 | |
| Theratechnologies INC. | $72.96 | 2023-2024 | Trogarzo, Egrifta |
| Exact Sciences Corporation | $60.94 | 2024 | Cologuard Collection Kit |
| Cipher Pharmaceuticals US LLC | $55.29 | 2025 | Spinosad, Natroba |
| Janssen Biotech, INC. | $53.24 | 2023 | Prezcobix, Symtuza |
| Astellas Pharma US INC | $46.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.25 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.95 | 2022 | |
| Corium, LLC | $32.20 | 2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $28.98 | 2024 | |
| Neurocrine Biosciences, INC. | $20.59 | 2023 | Ingrezza |
| Axsome Therapeutics, INC. | $20.35 | 2023 | Auvelity |
| Hologic Sales and Service, LLC | $20.14 | 2022 | |
| Lundbeck LLC | $17.15 | 2023 | Abilify Maintena |
| Ucb, INC. | $13.23 | 2021 | |
| Tris Pharma INC | $13.15 | 2023 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $12.78 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Blanks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.